Latest Breaking News On - Michael raizman - Page 1 : comparemela.com

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesEric donnenfeldCarl spanaMichael raizmanSecurities exchangePrnewswire palatin technologies incAmerican society of cataractSymptom endpoints including the coPalatin technologies incPositive phaseResults includedPrimary symptom endpointPain met statistical significanceWeek treatment periodMultiple symptom endpointsCo primary pain endpoint

Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Glaukos Corporation , an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today.

United statesDeborah ristvedtMichael raizmanValerie trubnikChristy bensonFritz hengererManjool shahEdward yungBlake williamsonI paul singhAli salimiJohn berdahlLike ahmedCristos ifantidesMitchell schultzBrandon ayres

Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease

/PRNewswire/ Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that.

United statesMichael raizmanCarl spanaExchange commissionDrug administrationSecurities exchangePalatin technologies incPalatin technologiesChief medical officerNew drug applicationDry eye diseaseMelanocortin receptor agonistsSecurities actSecurities exchange actPrivate securities litigation reform act

Palatin Presents Initial Dry Eye Disease Phase 3 Clinical Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference

/PRNewswire/ Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that.

United statesGeorgew ouslerMichael raizmanRobert jordanCarl spanaCora incPalatin technologies incSecurities exchangePrnewswire palatin technologies incExchange commissionAssociation of researchSevere dry eye diseaseResults fromClinical trialsGeorge ouslerDry eye disease

Palatin Technologies (PTN) Presents Initial Dry Eye Disease Phase 3 Clinical Data

Palatin Technologies (PTN) Presents Initial Dry Eye Disease Phase 3 Clinical Data
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesGeorgew ouslerMichael raizmanRobert jordanCarl spanaGeorge ouslerCora incAssociation of researchPalatin technologies incSevere dry eye diseaseResults fromClinical trialsDry eye disease